Should mannitol be administered preoperatively to older adult patients undergoing abdominal aortic aneurysm (AAA) repair to protect renal function?

Mannitol Use for AAA Repair: Not Recommended for Routine Renal Protection

Mannitol should not be administered solely for renal protection during abdominal aortic aneurysm (AAA) repair, as pharmacological agents including mannitol have not been demonstrated to provide renal protection during aortic surgery. 1

Guideline-Based Recommendations

The 2010 ACC/AHA/AATS guidelines provide contradictory recommendations that require careful interpretation:

Class III Recommendation (Do Not Use)

• Furosemide, mannitol, or dopamine should not be given solely for the purpose of renal protection in descending aortic repairs (Level of Evidence: B) 1
• The guidelines explicitly state: "Pharmacological agents, including mannitol, furosemide, or dopamine, have not been demonstrated to provide renal protection during descending thoracic aortic repair" 1

Class IIb Recommendation (May Be Reasonable)

• Preoperative hydration and intraoperative mannitol administration "may be reasonable" for renal function preservation in open repairs of the descending aorta (Level of Evidence: C) 1

The Class III recommendation takes precedence because it is based on higher-quality evidence (Level B vs. Level C) and directly addresses the question of using mannitol specifically for renal protection.

Clinical Context and Evidence Interpretation

Important Distinction

The guidelines address descending thoracic aortic and thoracoabdominal repairs, not specifically infrarenal AAA repair. However, the physiological principles and evidence apply similarly.

When Mannitol May Have Benefit

Recent research suggests nuanced findings:

• Suprarenal clamping with chronic kidney disease: Mannitol use was associated with reduced need for postoperative hemodialysis in patients with baseline CKD (Cr >1.8 mg/dL) undergoing suprarenal aortic clamping 2

• Mortality benefit: A 2025 study found mannitol associated with lower 30-day mortality in suprarenal clamping cases (7.3% vs 18.2%, adjusted HR 0.63, P<0.001), though this may reflect cardioprotective rather than renal protective effects 3

• Subclinical injury reduction: One small RCT (1996) showed reduced urinary albumin and N-acetyl glucosaminidase levels with mannitol, suggesting decreased subclinical glomerular and tubular damage, though no difference in clinical renal failure rates 4

When Mannitol Shows No Benefit

• Infrarenal clamping: No clinically important benefit over volume expansion alone in preventing GFR changes 5

• Standard AAA repair: The renal protective effect appears limited to patients with pre-existing CKD undergoing suprarenal clamping 2

Practical Algorithm

For Infrarenal AAA Repair

1. Do not use mannitol for routine renal protection
2. Focus on adequate preoperative hydration and maintaining hemodynamic stability
3. Avoid nephrotoxic drugs perioperatively

For Suprarenal/Juxtarenal AAA Repair

1. If patient has CKD (Cr >1.8 mg/dL): Consider mannitol 0.25-1.0 g/kg IV 1, 6
2. If normal renal function: Mannitol not indicated for renal protection alone
3. Timing: Administer before aortic cross-clamping if used 4, 7
4. Alternative strategies: Cold crystalloid renal perfusion during renal artery exposure (Class IIb) 1

Critical Caveats

Mannitol Risks

• Requires careful evaluation of circulatory and renal reserve 6
• Monitor fluid and electrolyte balance closely 6
• Risk greater in elderly patients with impaired renal function 6
• Can cause volume overload in patients with cardiac dysfunction

What Actually Works

The evidence consistently shows that maintaining adequate mean arterial pressure and avoiding nephrotoxic drugs are more important than any specific pharmacological intervention 8. The 25% acute renal failure rate after descending thoracic aortic repair is driven by:

• Age >50 years
• Pre-existing renal dysfunction
• Duration of renal ischemia
• Massive transfusion (>5 units)
• Hemodynamic instability 1

The Bottom Line

Optimize hemodynamics, minimize ischemia time, and ensure adequate hydration rather than relying on mannitol for renal protection. If mannitol is used, it should be in the specific context of suprarenal clamping with baseline CKD, where some evidence supports benefit, and the decision should account for potential cardioprotective effects rather than expecting definitive renal protection.